Myeloid Populations in Systemic Autoimmune Diseases
AbstractSystemic autoimmune diseases (SADs) encompass a wide spectrum of clinical signs as a reflection of their complex physiopathology. A variety of mechanisms related with the innate immune system are in the origin of the loss of self-tolerance in these diseases, and for most of them, the myeloid leukocytes are key actors. Monocytes, macrophages, dendritic cells, and neutrophils are first-line immune effectors located in the interface between innate and adaptive immunity. They are crucial in the organization of the local and systemic responses to damage-associated molecular patterns (DAMPs) and determine the intensity, orientation, and duration of the local immune response through the expression of chemokines, costimulatory or protolerogenic factors. In this review, we summarize the current knowledge about the role of the main myeloid populations in the induction and maintenance of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary antiphospholipid antibody syndrome (PAPS), systemic sclerosis (SSc), and Sj ögren’s syndrome (SjS), based on the data from both mouse preclinical models and patients. According to these data, our challenge in the next few years is to better dissect the fine mechanisms underlying the pathological role of myeloid cells in these diseases in order to define specific cell sub sets or proteins that can be potential targets for drug development.
A study by academics at the Shinshu University in Nagano, Japan, has discovered a daily dose of green tea can help to lower a person's blood pressure and also help to regulate weight.
Publication date: Available online 8 April 2020Source: Journal of Clinical Orthopaedics and TraumaAuthor(s): V. Adukia, J. Mangwani, R. Issac, S. Hussain, L. Parker
Publication date: Available online 8 April 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): David Kremer, Vivien Weyers, Joel Gruchot, Peter Göttle, Hans-Peter Hartung, Hervé Perron, Patrick Küry
With so many of us wrestling with fears and unknowns surrounding the coronavirus pandemic, every throat tickle, nose drip, or cough is suspect: do I have coronavirus? By now, we all know that COVID-19, the illness caused by coronavirus, can cause severe, life-threatening symptoms, although the majority of people who have it will experience a mild to moderate version. Of course, it is spring, so many people may be experiencing their annual springtime tree pollen allergies. Colds also remain common, just as was true before the coronavirus. And although influenza season is coming to an end, perhaps you’ve wondered if so...
People with stiff and aching knees due to arthritis get better relief from physical therapy than from cortisone injections, according to a one-year military study comparing the two treatments.Reuters Health Information
Conclusion: ART may reduce the risk of NCIs in HIV-infected patients in general. Further research to investigate NCIs on specific antiretroviral regimens and comorbidities may provide insights regarding the long-term clinical care of these patients.
Authors: van Kampen V, Hoffmeyer F, Monsé C, Raulf M, Brüning T, Bünger J, Sucker K Abstract Atopic, allergic, and especially asthmatic subjects might be particularly susceptible to sensory irritation induced by airborne chemicals compared to healthy individuals. Therefore, a good characterization of subjects is essential in inhalation exposure studies on sensory irritants. A total of 105 volunteers, 87% of whom reported to be non-allergic, participated in a medical examination that included skin prick test (SPT), measurements of total IgE, specific IgE (sIgE) to an ubiquitous allergen mix (sx1), a...
Conclusions/interpretationOur analysis identifies a range of demographic and environmental factors associated with type 1 diabetes in children in England.
Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron's chief scientific officer told Reuters.
Authors: Phaw NA, Dyson JK, Jones D Abstract Introduction: Primary biliary cholangitis (PBC) is a progressive inflammatory autoimmune cholestatic liver disease. Without treatment, it may result in fibrosis and eventually end stage liver disease. In addition to the disease burden, the symptom impact on the quality of life for PBC patients is significant. Ursodeoxycholic acid, and the second-line therapy Obeticholic acid, are the only available licenced treatments. Although there has been rapid development of novel therapies in recent years for the treatment of PBC, there are very few symptoms directed therapies.Area...